Apixaban
Apixaban is a pharmaceutical drug with 199 clinical trials. Currently 30 active trials ongoing. Historical success rate of 88.3%.
Success Metrics
Based on 121 completed trials
Phase Distribution
Phase Distribution
22
Early Stage
32
Mid Stage
84
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
84.0%
121 of 144 finished
16.0%
23 ended early
30
trials recruiting
199
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Anticoagulation in Patients With Venous Thromboembolism and Cancer
Clinical Trials (199)
Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Anticoagulation in Patients With Venous Thromboembolism and Cancer
Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis
Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease
Apixaban Versus Warfarin for Left Ventricular Thrombus
Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
Bariatric Surgery and Pharmacokinetics of Apixaban
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Thromboprophylaxis in Lower Limb Immobilisation
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Comparison of Apixaban Versus Enoxaparin
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 199